R-56865 acts as an antiarrhythmic by inhibiting spontaneous Ca2+ release from the sarcoplasmic reticulum mediated by the Na(+)-Ca2+ exchanger in cardiac myocytes.
Answers are grounded in this paper and cite their sources.
May guide selective antiarrhythmic development targeting Na-Ca exchanger-mediated Ca2+ release; leaves open translation to human arrhythmias.
Voltage-clamp studies were performed on guinea pig ventricular myocytes to clarify the action of N-(1-[4-(4-fluorophenoxy)butyl]-4-piperidinyl)-N-methyl-2-benzothiazo lamine (R-56865), an inhibitor of cardiac glycoside-induced arrhythmias. Transient inward current ((Iti)) was induced using low-K+/high-Ca2+ Tyrode solution. R-56865 (1 mM) was found to abolish I(ti). R-56865 had no influence on the peak Ca2+ current, steady-state current during the clamp, holding current, or the Ni(2+)-sensitive electrogenic Na(+)-Ca2+ exchange current. Fluorescence transients after repolarization (temporally related to the I(ti)) were abolished by R-56865 without affecting the fluorescence transients during depolarization. In separate experiments, the threshold of Ca2+ release from sarcoplasmic reticulum (SR) by the Ca2+ current was found to be unchanged, whereas Ca2+ transients (presumably triggered by Ca2+ entry through the Na(+)-Ca2+ exchanger) were depressed. Our results suggest that R-56865 inhibits spontaneous Ca2+ release from the SR when it is mediated by Ca2+ entry through the Na(+)-Ca2+ exchanger but that it has no direct effect on the well-known "physiological" Ca(2+)-induced Ca(2+)-release mechanism from SR.
No takes yet. Share an insight, caveat, or question.
Ichikawa et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: